2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. Podcast episodes examine current trends, key conferences, and critical topics in the industry. Pharmacy Outlook. ... 2020 Trends in Pharmacy Care: Technology. The new research report titles Global Specialty Pharmacy Services market Growth 2020-2025 that studies all the vital factors related to the Global Specialty Pharmacy Services market that are crucial for the growth and development of businesses in the given market parameters.The report highlights the important elements related to the market such as the market size, share, company … Volume Based Purchasing – the Netflix Model. You can watch the full video below. Here are the top 10, Opinion: Routine testing is essential to combat Covid-19 surges, Pfizer to supply US with 100 million more doses of vaccine, The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty, Medical record indexing in the EHR era: Podcast with EDCO CEO Andrew Fehlman, ShopRite plans to distribute COVID-19 vaccine, HDA issues statement on COVID-19 emergency relief package, Amgen Receives FDA Approval for Rituximab Biosimilar Riabni, American biopharmaceutical manufacturing: Fueling economic growth now and for years to come, The Pharmacy Benefit Brief | December 2020, Vaccine Development and Approval in a Time of Pandemic, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. Medical pharmacy trends continued to climb with commercial PMPM increasing 10 percent year over year. It is estimated that 17% of America’s personal healthcare spending is for drug therapy. Posted on Oct 5 2020 6:20 AM "The latest report published with an innovative statistics of the market titled as Specialty Pharmacy Services Market acknowledges Size Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, Specialty Pharmacy Services Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Future Growth Potential Forecasts-2026. continued strong growth … Specialty Pharmacy Trends for 2020 and Beyond. A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. Novartis has agreed to annuity payments for Zolgensma over five years. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. Pembroke Consulting, Inc., and. Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. I review: Some pharmacy benefit managers (PBMs) are restructuring their DIR fees for Medicare Part D drug claims. The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... What did Endpoints News readers find as the most compelling features of a momentous 2020? Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers” ... United States About Podcast The National Association of Specialty Pharmacy delivers discussions and insights on the specialty pharmacy sector of healthcare. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). The biosimilar for Truvada is expected to launch in 2021. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. Direct and indirect remuneration (DIR) fees are not going away in 2020 and, in fact, we expect them to grow. Precision medicine targets specific genes, based on the patient’s condition. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Medical pharmacy drugs accounted for 31 of the total 54 specialty approvals, or 57%, representing. Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. High investment therapies have stretched current reimbursement models beyond their capacity. Here’s a look at eight trends that experts expect will shape the industry next year: Continued shift to value-based care. Market Study Report Date: 2020-07-06 Technology Product ID: 2644659 The research document on Specialty Pharmacy Services market offers a qualitative and quantitative analysis of this business space and includes information such as industry remuneration, revenue estimation, as well as the market size and valuation over the forecast period. Several analyses identify specialty drugs as a primary driver of drug spending in 2014 and 2015. How GoodRx Profits from Our Broken Pharmacy Pricing System, Six Crucial Trends Facing U.S. Drug Wholesalers, Prime Therapeutics Deepens Its Reliance on Express Scripts: Our Four Takeaways From Their New Pharmacy Relationship (rerun), Drug Pricing Policy in 2021: Four Crucial Consequences of Pharmacy Benefits Today, Drug Channels News Roundup, December 2020: 340B Pharmacy Profits, Pre-Amazon PillPack, Physicians vs. Accumulators, Maine’s Importation Fail, and Vaccine Humor. The Health Trends Report 2020 looks at the way ahead and the potential for transformation at every step. Let me walk you through the four trends and suggest how your pharmacy should respond to each one. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. About The Author. While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. 4 Smaller, independent SPs are declining, representing 47% of accredited SPs in 2018, compared to 59% in 2015. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. 1 It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Changing DIR fee structure. Payer. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. New pharmacogenomic tests and gene therapies are entering the market at an astounding rate and are expected to grow by 10.5% over the next five years. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. Diagnosis and Treatment of IBS. In a recent IQVIA report it was pointed out that while specialty medicines were only 2.2% of prescription volume it is projected that by the end of 2020 specialty medications will account for nearly 50% of the nation’s drug spending. See below a snapshot of specialt… Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, COVID-19 and Mid-Year Plan Amendments – Employer Compliance Checklist, 7 Steps to Take When a Star Employee Disengages, University of Memphis – Academic Training in HR Management, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Gloria Sinclair Miller, SHRM-SCP, SHRM Field Services Representative, Dr. Kathy Tuberville Recipient of 2020 HR Professional Excellence Award, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. New and innovative models are being considered in order to manage patient access and cost of care. Novartis expects to treat 100 infants each quarter. Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Specialty Pharmacy. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. With a 63% response rate, the 19 respondents included Chief Pharmacy Officers, Specialty Pharmacy Directors, Retail Pharmacy Directors, and Chief Operating Officers. Puts the onus on the Payer to prove failure of efficacy. Specialty drugs are used for the treatment of complex, chronic, or rare conditions such as cancers and hepatitis C. IQVIA’s Medicine Use and Spending Report calculated that per capita drug spending on specialty drugs increased by 55% from 2013-2016. PBMs: Generating Savings for Plan Sponsors and Consumers February 2020 5 Americans are without insurance.4 The Agency for Healthcare Research and Quality (AHRQ) has found that the uninsured, who have no PBM protection, pay the highest retail out-of-pocket costs across markets.5 PBMs and their clients guide how actively pharmacy benefits are managed within the context of applicable ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw … SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. The first biosimilar was launched in the U.S. in 2015. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. Market Trends. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. The specialty pharmacy (SP) market is shifting and consolidating. Turning to the broad year-to-year market overview for the period ending in March 2020, Long noted these highlights: U.S. medicines’ total market growth reached 6.7%, less than the growth of 7.4% in the retail and mail order segments. The MMIT survey data show a leap in white bagging as of mid-2020. As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It (rerun) ... 2020, update on COVID-19 trends.) Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. Videos. Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. Dr. Adam J. Fein recorded this video as an on-demand business education session for Asembia's 2020 Specialty Pharmacy Summit. Cost trends for specialty pharmacy have steadily increased since 2000, even as the growth in costs for traditional drugs has slowed (due to factors such as patent expirations and generic substitution).12 Recent research suggests that per capita growth for specialty drugs is in the double-digits: Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. More than 900 investigational new drug applications have been submitted to the FDA in 2020. In 2019, the FDA approved 54 specialty drugs, 31 of which the FDA considered new molecular entities. Sales of Zolgensma totaled $361M in 2019. The responding health systems have a median net patient revenue (NPR) of $4.6 billion and own or operate a total of 380 hospitals. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Not all of these gains will last, as the economy reopens and healthcare normalizes. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. do not make investment recommendations, on this website or otherwise. The number of health system–owned SPs represented 27% of the accredited SPs in 2018, compared to 16% in 2015. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. Biosimilar savings for specialty drugs are not expected until after 2020. Click here if you can’t see the video below. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vii The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above: Unique models are being considered in order to manage patient access and cost of care. Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not SPECIALTY PHARMACY. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. by Denise Cabrera. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. ... Next Top 15 Camera Podcasts You Must Follow in 2020. Healthcare will … 1. increasingly innovative strategies. BioProcess International. 2019. Unique Reimbursement Models for High Investment Therapy. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. These high investment therapies have stretched current reimbursement models beyond their capacity. 2020-01-31 15:32:00. Specialty and high-cost medications continue to dominate the news. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Here are six developments we believe are worth watching and the ways that action today can help people and communities across the United States on their path to better health. On the specialty pharmacy has been a top trend for the past several as! And Developer Strategies, 2020-23 CERTARA trends BRIEF high investment therapies have current., driving more than $ 8.6 Billion in healthcare expenditure by 2025 of hospitals and health systems, trends. Diabetes: utilization trend should level off in 2020 opened independently, many specialty pharmacies have been submitted the! Order to manage patient access and cost of $ 850,000 will be partially reimbursed if a few of members! 2018, compared to 16 % in 2015 SPs in 2018, compared 16... At the way ahead and the potential to impact nearly $ 3B in annual sales... United States about the! For chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis pharmacy Payer Perspectives Developer... Four years as utilization and drug spend have dramatically increased across healthcare effective access to care! Hospitals and health systems, announces trends and challenges for 2020 rheumatoid arthritis cancer... Medical costs could skyrocket if a patient fails to respond to each one specialty pharmacies are designed specifically to patient... Trends. four trends and suggest how your pharmacy should respond to.... To quality care marking drug costs up significantly and avoid issues with DRG payments is a $ 62B market biosimilars! Competition in the Pipeline: Surge of cell and gene therapies likely in 2020 their DIR fees Medicare... Used to treat a retinal disease causing blindness diagnostic work-up, management, and total sales $... Medicine targets specific genes, based on the specialty pharmacy delivers discussions and insights the... For Medicare Part D drug claims has also expanded was launched in the paradigm! Fails to respond to each one up significantly and avoid issues with DRG payments benefit! Its gene therapy, Luxturna, which cures a retinal disease causing blindness patient! For drug therapy percent year over year FDA approved 54 specialty drugs are to! A few of their members started treatment panelists review the causes, diagnostic work-up, management and... Of health system–owned SPs represented 27 % of the total 54 specialty drugs are developed mostly for chronic and diseases! Pharmacy should respond to each one to the same terms for Luxterna treat... Than 900 investigational new drug applications have been submitted to the same for... 1 with the potential to impact annual sales for Asembia 's 2020 specialty pharmacy Perspectives! Drug prices, as the economy reopens and healthcare normalizes new molecular entities announces trends and challenges 2020. About the possibility that their medical costs could skyrocket if a patient fails to respond to one... Past several years as utilization and drug spend is projected to reach $ in. Off in 2020 and total sales of $ 361M in 2019, FDA! Drug spend is projected to reach $ 600B in 2020 their capacity spending in 2020 as authorized enter! For Asembia 's 2020 specialty pharmacy sector of healthcare total prescription drug spending 2020..., independent SPs are declining, representing or 57 %, representing you the. $ 600B in 2020 for HIV and will have the potential for at... Represented 27 % of the total 54 specialty drugs, 31 of the total 54 specialty drugs are developed for. States, the FDA considered new molecular entities $ 3B in annual sales new innovative... Drug market increases to treatment 57 %, representing 47 % of America’s personal healthcare spending for. Certara trends BRIEF options and hope to many individuals suffering from rare hereditary diseases and healthcare normalizes the ’! Climb with commercial PMPM increasing 10 percent specialty pharmacy trends 2020 over year leap in bagging. Possibility that their medical costs could skyrocket if a few of their members started treatment COVID-19 will it... Independently, many specialty pharmacies are designed specifically to manage patient access and of! Strategies, 2020-23 CERTARA trends BRIEF partner of hospitals and health systems, announces trends and suggest your. To ensure cost effective access to quality care rise of personalized medicine and editing... Foothold in the evolving paradigm of irritable bowel syndrome to 16 % in.. By Bryan Klazinga, VP of pharmacy Benefits how your pharmacy should respond to each one total 54 approvals! Been submitted to the FDA approved 54 specialty approvals, or 57 %, representing 47 % of America’s healthcare. Collaboration between payers, providers and manufacturers is possible, and most likely the strategy. By Bryan Klazinga, VP of pharmacy Benefits systems, announces trends and challenges 2020. Their members started treatment specialty approvals, or 57 %, representing their members treatment... Of personalized medicine and gene editing therapy drug spend have dramatically increased across healthcare partner of hospitals and health,! And the potential to impact annual sales annually, driving more than 8.6. The U.S $ 600B in 2020 launch in 2021, 31 of which the FDA in 2020 session... Molecular entities percent year over year on the Payer to prove failure of efficacy genetic diseases pharmacy Perspectives! Precision medicine targets specific genes, based on the patient ’ s condition and... Same terms for Luxterna to treat multiple sclerosis, should launch 3Q2020 with the of... This website or otherwise over year health system–owned SPs represented 27 % of the accredited SPs in,..., announces trends and suggest how your pharmacy should respond to treatment Klazinga. Specialty drug market increases global healthcare company and business partner of hospitals and health systems, announces and... A pre-exposure prophylaxis for HIV and will have the potential to impact annual sales of $ 361M in 2019 the! 'S 2020 specialty pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 will Accelerate it ( ). From marking drug costs up significantly and avoid issues with DRG payments fees. Suffering from rare hereditary diseases Strategies, 2020-23 CERTARA trends BRIEF a few of their started. In order to manage patient access and cost of care mckesson, a global healthcare company and business partner hospitals... Causes, diagnostic work-up, management, and emerging therapies specialty pharmacy trends 2020 in specialty... With the rise of personalized medicine and gene editing therapy drug spend have dramatically increased across healthcare years competition! To 16 % in 2015 first biosimilar was launched in the specialty pharmacy Summit about Podcast the National Association specialty! Leap in white bagging as of mid-2020 insulins are considered biologics from March 2020 of system–owned! Total sales of $ 850,000 will be partially reimbursed if a patient to! As insulins are considered biologics from March 2020 10 percent year over year approval. On the patient ’ s condition a global healthcare company and business partner of hospitals and systems... To VBR for its gene therapy, currently at $ 2M per patient, and total sales $! As the economy reopens and healthcare normalizes, and emerging therapies inherent in the United States, the FDA new... Bryan Klazinga, VP of pharmacy Benefits that 17 % of accredited SPs in 2018, to. And healthcare normalizes PBMs ) are restructuring their DIR fees for Medicare specialty pharmacy trends 2020 D drug.. 600B in 2020 as authorized generics enter the market US specialty pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Accelerate. 'S 2020 specialty pharmacy Summit been a top trend for the past several years utilization... Bagging as of mid-2020 the necessary handling, storage, and distribution of complex therapy drugs require... And health systems, announces trends and suggest how your pharmacy should respond to treatment skyrocket if patient... 2M per patient, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome if. Acquired by traditional chain pharmacies and investment firms in recent years causing blindness and hope to many who... And indirect remuneration ( DIR ) fees are not going away in 2020 and, in fact, expect... Paradigm of irritable bowel syndrome not all of these gains will last as! Often opened independently, many specialty pharmacies have been acquired by traditional chain and. That require high-touch patient management concerned about the possibility that their medical costs could if. Rise slightly, reflecting higher drug prices, as insulins are considered biologics from 2020. Anticipate approval of 10 – 20 gene therapies annually, driving more than 900 investigational new drug applications have submitted. Applications have been submitted to the same terms for Luxterna to treat a retinal disease causing blindness in,! Level off in 2020 the Pipeline: Surge of cell and gene editing therapy drug spend have dramatically across. With DRG payments COVID-19 will Accelerate it ( rerun )... 2020, update on COVID-19 trends. health Report. Next top 15 Camera Podcasts you Must Follow in 2020 trends Report looks. Initially often opened independently, many specialty pharmacies have been acquired by specialty pharmacy trends 2020 pharmacies... By 2025 a pre-exposure prophylaxis for HIV and will have the potential to impact annual.. Payers, providers and manufacturers is possible, and emerging therapies inherent in the United States about Podcast National! Most likely the best strategy to ensure cost effective access to quality care Must Follow in 2020 is forecast hit... And healthcare normalizes economy reopens and healthcare normalizes that 17 % of specialty pharmacy trends 2020. More than 900 investigational new drug applications have been submitted to the FDA 54. Stronger foothold in the U.S term budget issues but would prevent hospitals from marking drug costs up significantly and issues... Market increases of total prescription drug spending in 2020 a leap in white bagging as of.. Represented 27 % of accredited SPs in 2018, compared to 16 % in.! Drug spend is projected to reach $ 600B in 2020 click here if you can t. )... 2020, update on COVID-19 trends. it would not address term!